Basu Paramita, Santos Diogo F S, Gakii Nina, Gralinski Margaret R, Griggs Ryan B, Brings Sebastian, Fleming Thomas, Susuki Keiichiro, Taylor Bradley K
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Neuroscience, Cell Biology, and Physiology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.
Pain Rep. 2025 Aug 12;10(5):e1312. doi: 10.1097/PR9.0000000000001312. eCollection 2025 Oct.
Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)RE, and here evaluated its antihyperalgesic efficacy in the db/db mouse model of type II diabetes painful diabetic neuropathy.
To test the hypothesis that CycK(Myr)RE can reduce behavioral and molecular signs of painful diabetic neuropathy.
We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal-regulated kinase as a measure of neuronal activity in spinal cord dorsal horn.
We report that a single systemic injection of CycK(Myr)RE (3 mg/kg) reversed heat hypersensitivity. Repeated systemic injection of CycK(Myr)RE (0.125 mg/kg, 3 times per week, 6-12 weeks of age) prevented heat hypersensitivity and reduced stimulus-evoked phosphorylated extracellular signal-regulated kinase.
These studies promote CycK(Myr)RE as the most promising MG scavenger for the prevention and treatment of hyperalgesia in type 2 diabetic neuropathic pain.
甲基乙二醛(MG)是葡萄糖的一种反应性二羰基产物,其病理水平会导致与II型糖尿病相关的主要神经并发症,包括慢性神经性疼痛。针对MG水平升高的策略包括小分子MG清除剂,但清除剂在蛋白水解稳定性和清除活性起效方面的不足阻碍了其临床应用。为填补这一空白,我们开发了一种长效且高反应性的环肽CycK(Myr)RE,并在此评估了其在II型糖尿病性疼痛性糖尿病神经病变的db/db小鼠模型中的抗痛觉过敏疗效。
检验CycK(Myr)RE可减轻疼痛性糖尿病神经病变的行为和分子体征这一假设。
我们评估热超敏反应作为痛觉过敏的指标,并评估脊髓背角中磷酸化细胞外信号调节激酶的触觉诱发表达作为神经元活动的指标。
我们报告单次全身注射CycK(Myr)RE(3毫克/千克)可逆转热超敏反应。重复全身注射CycK(Myr)RE(0.125毫克/千克,每周3次,6至12周龄)可预防热超敏反应并减少刺激诱发的磷酸化细胞外信号调节激酶。
这些研究表明CycK(Myr)RE是预防和治疗2型糖尿病性神经病变疼痛中痛觉过敏最有前景的MG清除剂。